Patients, disease, and transplant characteristics
| . | Reduced-intensity regimens . | Myeloablative regimens . | P . |
|---|---|---|---|
| Number of patients | 39 | 141 | |
| Age (y) | .70 | ||
| ≤10 | 14 (36%) | 52 (37%) | |
| 11-18 | 25 (64%) | 89 (63%) | |
| Sex | .87 | ||
| Male | 19 (49%) | 73 (52%) | |
| Female | 20 (51%) | 68 (48%) | |
| Performance score | .05 | ||
| 90-100 | 24 (62%) | 112 (79%) | |
| 60-80 | 13 (33%) | 24 (17%) | |
| Not reported | 2 (5%) | 5 (4%) | |
| Recipient cytomegalovirus serostatus | .08 | ||
| Negative | 8 (21%) | 52 (37%) | |
| Positive | 31 (79%) | 89 (63%) | |
| Disease status at transplantation | .90 | ||
| CR1 | 14 (36%) | 56 (40%) | |
| 2nd complete remission | 20 (51%) | 67 (48%) | |
| Relapse or induction failure * | 5 (13%) | 18 (13%) | |
| Cytogenetic risk group† | .99 | ||
| Favorable | 6 (15%) | 21 (15%) | |
| Intermediate | 27 (70%) | 99 (70%) | |
| Poor | 6 (15%) | 21 (15%) | |
| Donor type‡ | .003 | ||
| HLA-matched sibling | 5 (13%) | 40 (28%) | |
| Matched unrelated | 18 (46%) | 28 (20%) | |
| Mismatched unrelated | 16 (41%) | 73 (52%) | |
| Graft type | .92 | ||
| Bone marrow | 14 (36%) | 55 (39%) | |
| Peripheral blood | 13 (33%) | 43 (30%) | |
| Cord blood | 12 (31%) | 43 (30%) | |
| GVHD prophylaxis | .17 | ||
| Tacrolimus containing | 14 (36%) | 35 (24%) | |
| Cyclosporine containing | 25 (64%) | 106 (75%) | |
| Median (range) follow-up (mo) | 60 (12-97) | 47 (3-121) |
| . | Reduced-intensity regimens . | Myeloablative regimens . | P . |
|---|---|---|---|
| Number of patients | 39 | 141 | |
| Age (y) | .70 | ||
| ≤10 | 14 (36%) | 52 (37%) | |
| 11-18 | 25 (64%) | 89 (63%) | |
| Sex | .87 | ||
| Male | 19 (49%) | 73 (52%) | |
| Female | 20 (51%) | 68 (48%) | |
| Performance score | .05 | ||
| 90-100 | 24 (62%) | 112 (79%) | |
| 60-80 | 13 (33%) | 24 (17%) | |
| Not reported | 2 (5%) | 5 (4%) | |
| Recipient cytomegalovirus serostatus | .08 | ||
| Negative | 8 (21%) | 52 (37%) | |
| Positive | 31 (79%) | 89 (63%) | |
| Disease status at transplantation | .90 | ||
| CR1 | 14 (36%) | 56 (40%) | |
| 2nd complete remission | 20 (51%) | 67 (48%) | |
| Relapse or induction failure * | 5 (13%) | 18 (13%) | |
| Cytogenetic risk group† | .99 | ||
| Favorable | 6 (15%) | 21 (15%) | |
| Intermediate | 27 (70%) | 99 (70%) | |
| Poor | 6 (15%) | 21 (15%) | |
| Donor type‡ | .003 | ||
| HLA-matched sibling | 5 (13%) | 40 (28%) | |
| Matched unrelated | 18 (46%) | 28 (20%) | |
| Mismatched unrelated | 16 (41%) | 73 (52%) | |
| Graft type | .92 | ||
| Bone marrow | 14 (36%) | 55 (39%) | |
| Peripheral blood | 13 (33%) | 43 (30%) | |
| Cord blood | 12 (31%) | 43 (30%) | |
| GVHD prophylaxis | .17 | ||
| Tacrolimus containing | 14 (36%) | 35 (24%) | |
| Cyclosporine containing | 25 (64%) | 106 (75%) | |
| Median (range) follow-up (mo) | 60 (12-97) | 47 (3-121) |
Matched unrelated in RIC group: cord blood (n = 1), bone marrow (n = 7), peripheral blood (n = 10); matched unrelated in MAC group: cord blood (n = 1), bone marrow (n = 14), peripheral blood (n = 13); mismatched unrelated in RIC group: cord blood (n = 11), bone marrow (n = 3), peripheral blood (n = 2); and mismatched unrelated in MAC group: cord blood (n = 42), bone marrow (n = 18), peripheral blood (n = 13).
Disease status at transplant was primary induction failure for 1 patient in the RIC group and 7 patients in the MAC group.
Cytogenetic risk group: favorable risk group included the t(8;21), t(15;17), and inv(16); high risk was defined by the presence of -7, -5, del (5q), abnormalities of the long arm of chromosome 3, or complex karyotype that was defined as more than 4 abnormalities; all other AML karyotypes were classified as intermediate risk.
For unrelated donor transplantation, an HLA-match was considered allele-level HLA typing at HLA-A, -B, -C, and -DRB1. For umbilical cord blood transplantation, HLA-matching was considered a low-resolution match at HLA-A and -B, and allele level at -DRB1.